In this study, we further investigated the clinical benefits of CDK4/6 inhibitors on HR+ and HER2- advanced breast cancer using the latest reports to evaluate long-term clinical benefits and study the impact of biomarkers on the efficacy of CDK4/6 inhibitors, as well as compare the effectiveness of different CDK4/6 inhibitors in specific populations. This evidence concerns the gene ERBB2 and breast carcinoma.